Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir113
Comorbidities and the right dose: antipsychotics106
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update68
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects60
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata57
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury50
Hormones, microbes, and PrEP drugs in the female genital tract45
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis32
Guidance for interactions between antiseizure medications32
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria27
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine27
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database25
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer23
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis23
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update21
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals20
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury19
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study19
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease19
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase19
0.056822776794434